Press Release

Glythera appoints Professor Kerry Chester to SAB

Appointment supports the development of the Company’s pipeline  Glythera Limited (Glythera), the next-generation antibody drug conjugate (ADC) development company, today announces that it has appointed Professor Kerry Chester to its Scientific Advisory Board (SAB). Professor Chester’s appointment strengthens the Company’s SAB and will help shape its portfolio of ADCs for targeting previously untreatable cancers. Professor Chester leads the Antibody Engineering Group at University College London (UCL) Cancer Institute and has over 20 years’ experience in antibody engineering, antibody phage-display technology…

Read more>>

Glythera appoints Chief Scientific Officer and strengthens SAB

Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates Dr Jon Roffey appointed to Scientific Advisory Board Newcastle, UK, 17th January, 2018: Glythera Limited (Glythera), the next generation antibody drug conjugate (ADC) development company, is pleased to announce the appointment of Dr Robert Lutz as Chief Scientific Officer. Dr Lutz will lead the advancement of Glythera’s portfolio of Antibody Drug Conjugates (ADCs) in the treatment of difficult-to-treat cancers. In addition, Glythera has appointed Dr…

Read more>>

Positive Outcome of Proof-of-Concept Study with Glythera and Follow on Drug Development Partnership

Successful proof-of-concept study leads to Affimer drug conjugate development partnership Affimers shown to have key technical benefits for drug conjugates Drug conjugate market expected to be worth $14.6bn by 2030 Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its initial study with Glythera Limited, the developer of next generation antibody drug conjugates, has concluded successfully.  Following this study the two companies have agreed the terms of a licensing deal which will allow…

Read more>>

 Last ›

Page 1 of 11